

Free-to-patient immune cell banking to supercharge cancer cell therapy access and innovation



achieveclinics.com Los Angeles CA

Highlights

- 1 We empower cancer patients to bank their immune cells for cell therapy (incl. pre-chemo) at no cost
- 2 With us, industry can now pre-enroll patients for studies and manufacture with "off-the-shelf" cells
- 3 Our unique platform generates invaluable large-format, patient records-linked research biomaterial
- 4 Free-to-patient model sustained by industry revenues: Signed LOIs reflect ~\$1m+ in immediate demand
- 5 Launch network incl. leaders from Genentech, Penn, Be The Match, xCures, +dozens in active pipeline
- 6 Initial oncologist support and collection (apheresis) sites expected in Seattle and Houston
- 7 Proudly endorsed by the Emily Whitehead Foundation (<https://emilywhiteheadfoundation.org/>)

Our Team



Paul Chun Chief Financial Officer, Co-Founder

~20 year biotech veteran with background in investment research, capital markets, corporate development, and financa. including public biotech Board of Directors. Track record of several IPOs, financings, licensing, etc., incl. in cancer immunotherapy.



Brad Heller Chief Executive Officer, Founder

UCSF-trained neuro and cell biology specialist with biopharma startup experience across CAR-TCR and drug discovery. Finally got fed up with seeing curative cell therapies get stuck behind apheresis appointment backlogs and chemo-cooked cells.

LEAD INVESTOR

Brazen Capital

Brazen Capital is launching the next generation of scientist-CEOs at the earliest stages of their startup journey in biomedicine. Our unique value-add is we (co-GEs Shawn Carbonell, MD, PhD and Monica Berrendo, PhD [YC W8]) have been scientist-CEOs ourselves for over a decade each. Unlike most VCs, we've lived that life. Brad Heller, PhD and I met randomly in November 2021 on LunchClub, of all places. This was a time before we had even launched the fund, but after listening to him passionately explain what he was working on during that short video conference call, I placed him in my mental pipeline of founders to potentially invest in. Over the subsequent months, what Monica and I confirmed is this is an impressive founder leveraging his deep technical expertise to solve a major problem he personally identified while working in the cell therapy industry. With the addition of highly experienced biotech executive and cofounder, Paul Chun, we are extremely bullish about their potential for dramatically improving patient outcomes in the multi-billion dollar cell therapy space. We are proud to be the first investors in Achieve Clinics and welcome you to join us. W. Shawn Carbonell, MD, PhD Founding Partner, Brazen Capital

Invested \$2,500 this round & \$10,000 previously

Pitch



Introduction

Aug 2023

Brad Heller, Co-Founder, CEO
brad@achieveclinics.com
Paul Chun, Co-Founder, CFO
paul@achieveclinics.com

Cancer cell therapy is transformative - but inaccessible



Peterson are powerless to access cell therapy early because they aren't eligible

Conventional treatment damages the cells used to make cell therapies¹

Less than 5%² of screened patients access a trial before it's too late


Prior treatment exposure, high costs, and cell collection capacity constraints make the potentially curative option of autologous cell therapy both harder to access and less likely to work

ACHIEVE CLINICS

1. Bhatia et al. (2019) *Journal of Clinical Oncology*
2. Hargrett-Parsons et al. (2019) *Journal of Clinical Oncology*
3. R. W. G. (2019) *Journal of Clinical Oncology*

Trials need better access to patients

Cell therapies like Yescarta work better when made from chemo-naïve cells



In addition, half of trials fail just because they did not enroll enough patients³.

ACHIEVE CLINICS

1. Research at COTI (2019) *Research & Innovation*
2. ASCO (2019) *Journal of Clinical Oncology*
3. *Science* (2019) *Journal of Clinical Oncology*

We streamline access by banking immune cells for free

1. Roster enrollment
2. ACT eligibility determined
3. Cell collection and banking
4. Cell therapy trials

Patients who may eventually qualify for our network's cell therapies provide consent and their access. **Patients do not pay.** Insurance is not billed.

Our partner network performs apheresis and banks immune cells from these patients (even before Phase treatment) at our expense.

Our roster of patients and inventory of starting material enables on-demand trial enrollment and manufacturing with best-in-class starting material.

ACHIEVE CLINICS

We boost research and clinical development

1. Roster enrollment
2. ACT eligibility determined
3. Cell collection and banking
4. Cell therapy trials

Patients provide informed consent to share both their cells and their P4H with Achieve Clinics partners.

Surplus or banked P4H not sent for manufacturing can be sold for research.

The revenue we generate from connecting patients to cell therapy innovation powers our free-to-patient model.

ACHIEVE CLINICS

The future we are building

A decentralized clinical site network for "off-the-shelf" autologous cell therapies

- ★ Achieve Clinics aph centers
- Recruiting trials that use the Achieve Clinics Process
- Trials that can work for Jane
- Cell processing and storage facility

Jane

Jane may live in rural Michigan, but we can do apheresis for her in Chicago and set her up for possible options in Houston or Seattle she would have been unlikely to access otherwise.

ACHIEVE CLINICS

Three revenue channels drive sustainability

Clinical / Commercial GMP Product, ~1x/pt. (C-18, T-12, etc.)

Clinical trial patient acquisition, commercial reimbursement, management (compliance, financing), apheresis capacity

Large Format Research Use, ~1-5x/pt. (C-125, T-12, T-110)

Process development, international scale-up costs

Small Format Research Use, < 100x/pt. (D-100m, T-12, T-110)

Cancer immunology research, TCR cloning, etc.

Clinical pack (GMP)


Process pack (RUO or GMP)

Process pack (RUO or GMP)

Biological research (RUO or GMP)

ACHIEVE CLINICS

Three revenue channels drive sustainability



Forward looking projections cannot be guaranteed.

Substantial addressable markets

We estimate there are presently **>1,000 clinical trials of autologous cancer cell therapies, seeking to enroll at least 20,000 patients**

- This volume of clinical activity should only grow as programs advance
- Market should also expand as cell therapy reaches larger solid tumor populations



Building an Exclusive Patient-Driven Ecosystem

Achieve Clinics will be an AI-powered marketplace enabling patients to both **access and accelerate** innovation across cancer cell therapy:

- As first mover,** Achieve will have the most robust and accessible roster available
- Our patient material supply will be exclusive and impenetrable, with zero churn**
 - Once patients bank their chemo-naïve cells with us and begin conventional treatment, the critical window will have closed. A competitor needs a time machine to take this patient from us.
- Through xCures, our roster is enhanced by a proprietary AI-powered EHR tool**
 - Our clinical site network will have an unparalleled link between patient cell tissue and real-time medical history

Achieve Clinics Founding Team

Brad Heiler, CEO

Mr. Heiler is a seasoned executive with over 20 years of experience in the biotech industry. He has held various leadership roles at major pharmaceutical and biotech companies, including Amgen, Genentech, and Novartis. He is currently a member of the Board of Directors at Amgen and Novartis. He holds a Bachelor's degree from the University of California, Berkeley.

Paul Chun, CFO/CBO

Mr. Chun is a financial executive with over 15 years of experience in the biotech industry. He has held various leadership roles at major pharmaceutical and biotech companies, including Amgen, Genentech, and Novartis. He is currently a member of the Board of Directors at Amgen and Novartis. He holds a Bachelor's degree from the University of California, Berkeley.

Advisory Board

Michael Bloch, MD PhD
Member of the Scientific Advisory Board at the Department of Cell and Tissue Biology, University of California, Berkeley.

Armita Wikstrom
Member of the Scientific Advisory Board at the Department of Cell and Tissue Biology, University of California, Berkeley.

Steven Dorn, MD
Member of the Scientific Advisory Board at the Department of Cell and Tissue Biology, University of California, Berkeley.

Heather Stofark, MD PhD
Member of the Scientific Advisory Board at the Department of Cell and Tissue Biology, University of California, Berkeley.

Andrew Ficzak, MD
Member of the Scientific Advisory Board at the Department of Cell and Tissue Biology, University of California, Berkeley.

Nirupama Pika, PhD
Member of the Scientific Advisory Board at the Department of Cell and Tissue Biology, University of California, Berkeley.

Shawn Carronell, MD PhD
Member of the Scientific Advisory Board at the Department of Cell and Tissue Biology, University of California, Berkeley.

Additional Affiliations / Endorsements

- Emily Whitehead Foundation**
 - "The Emily Whitehead Foundation is excited to support the efforts of Achieve Clinics and their mission to improve patient access to more effective cell therapies"
- Larta Institute Heal.LA Bioscience Accelerator**
 - Member of the 2023 awardee class
- xCures**
 - Pending agreement for integration of real-time electronic health records
 - May include potential revenues from anonymized patient data sharing

